WO1996039026A1 - Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells - Google Patents

Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells Download PDF

Info

Publication number
WO1996039026A1
WO1996039026A1 PCT/US1996/009005 US9609005W WO9639026A1 WO 1996039026 A1 WO1996039026 A1 WO 1996039026A1 US 9609005 W US9609005 W US 9609005W WO 9639026 A1 WO9639026 A1 WO 9639026A1
Authority
WO
WIPO (PCT)
Prior art keywords
red blood
blood cells
suspension
oxygen
storing
Prior art date
Application number
PCT/US1996/009005
Other languages
French (fr)
Inventor
Mark W. Bitensky
Tatsuro Yoshida
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to BR9608404-9A priority Critical patent/BR9608404A/en
Priority to CA002223130A priority patent/CA2223130C/en
Priority to DE69626204T priority patent/DE69626204T2/en
Priority to AU60470/96A priority patent/AU710467B2/en
Priority to AT96918133T priority patent/ATE232359T1/en
Priority to EP96918133A priority patent/EP0830058B1/en
Priority to JP50143097A priority patent/JP4303786B2/en
Publication of WO1996039026A1 publication Critical patent/WO1996039026A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts

Definitions

  • the present invention relates generally to the liquid preservation of blood and, more particularly, to the refrigerated storage of blood in the absence of oxygen.
  • the invention was made with government support under Contract No. W-7405-ENG-36 awarded by the U.S. Department of Energy to the Regents of The University of California. The government has certain rights in the invention. BACKGROUND OF THE INVENTION
  • the current blood supply is considerably smaller than the need therefor.
  • Stored blood is considered unusable after about 5-6 weeks of steady deterioration in storage as determined by the inability of such cells to survive in the circulation after transfusion, which in part is caused by hemoglobin oxidation and degradation and adenosine triphosphate (ATP) depletion.
  • ATP adenosine triphosphate
  • Red blood cells survive for about 4 months under conditions of turbulent flow in the body without protein synthesis.
  • Oxygen (0 2 ) is essential for the conversion of hemoglobin (Hb) to met-Hb, the breakdown of which produces toxic products such as hemichrome, hemin and free Fe 3+ . Together with 0 2 , these products catalyze the formation of hydroxyl radicals (OH «), and both OH* and the met-Hb breakdown products damage the red cell lipid membrane, the membrane skeleton, and the cell contents.
  • OH hydroxyl radicals
  • Refrigeration reversibly disables the enzymes essential for met-Hb reduction in vivo, increases the solubility of damaging O 2 (almost by a factor of 2) in the environment of the red blood cells, and permits the level of ATP to decrease by diminishing the glycolytic rate (at 4°C the rate is about 1% of that found at 37°C).
  • Reduction of red cell ATP concentration results in echinocyte (an unstable form of red blood cells) formation, increased rates of membrane vesiculation, loss of red cell surface area, and accelerated sequestration by splenic macrophages. Vesiculation continues throughout the cold storage period, is exacerbated by echinocyte formation, and decreases red blood cell survival by decreasing red blood cell membrane area.
  • Packed RBCs are suitable for transfusion following the removal of the supernatant with a single washing step.
  • Greenwalt et al. also conclude that factors other than ATP concentration appear to play an increasingly important role in determining RBC viability after 50 days of storage. They cite the results of L. Wood and E. Beutler in "The Viability Of Human Blood Stored In Phosphate Adenine Media," Transfusion 7, 401-408 (1967), find in their own experiments that the relationship between ATP concentration and 24-hour RBC survival measurements appears to become less clear after about 8 weeks of storage. E. Beutler and C.
  • Another object of the present invention is to provide a procedure for prolonged blood storage while minimizing the complexity of the procedures required for preparing transfusible samples.
  • the method for storing red blood cells hereof includes the steps of: mixing a sample of whole blood containing the red blood cells to be stored with an anticoagulant solution, forming thereby a first suspension of red blood cells, concentrating the red blood cells from the liquid portion (plasma) of the first suspension, forming thereby a mass of packed red blood cells, mixing the packed red blood cells so produced with an additive solution which includes glucose, adenine, and salts, forming thereby a second suspension of red blood cells, removing the oxygen from the second suspension of red blood cells, and cooling the second suspension of red blood cells to 4°C.
  • the method for storing red blood cells hereof includes the steps of: forming a mass of packed red blood cells, mixing the packed red blood cells with an additive solution which includes glucose, adenine, and salts, forming thereby a suspension of red blood cells removing the oxygen from the suspension of red blood cells, and cooling the suspension of red blood cells to 4°C.
  • Benefits and advantages of the present invention include the preservation of ATP levels and the reduction of hemolysis and accumulation of membrane vesicles in the refrigerated RBCs, as a consequence of creating an environment (0 2 removal) that prevents hemoglobin degradation, with the result that useful refrigerated storage periods may be prolonged.
  • FIGURE 1 shows the effect of different storage gases as a function of time on the quantity of membrane vesicles accumulated during storage of red blood cells treated with ammonium phosphate at 4°C.
  • FIGURE 2 shows the effect of different storage gases as a function of time on the rates of hemolysis during storage of red blood cells treated with ammonium phosphate at 4°C.
  • FIGURE 3 shows the effect of different storage gases as a function of time on the cellular ATP levels during storage of red blood cells at 4°C in the presence and absence of ammonium phosphate.
  • FIGURE 4 shows the effect of oxygen removal on total red blood cell ATP, extent of hemolysis, and quantity of shed vesicles for red blood cells stored for 3.5 weeks at 4°C, relative to an untreated control sample.
  • the present invention includes improvement of the in vivo survival characteristics of transfused red blood cells that have been stored at 4°C for prolonged periods of time by removing oxygen therefrom at the time of storage, and preventing any further exposure of the stored RBCs to oxygen.
  • the in vitro diagnostics of hemolysis, vesicle production and ATP levels when taken together, provide a useful indication of in vivo survival.
  • adenosine triphosphate levels within the stored red blood cells have been boosted in some samples by addition of ammonium phosphate.
  • Oxygen removal, and the effects of various additive solutions were investigated with red blood cells stored in standard polyvinyl chloride (PVC) blood bags with di-(2-ethylhexyl) phthalate (DEHP) plasticizer containing citrate, phosphate, sodium chloride, adenine, and dextrose (anticoagulant/buffer solution, AS3) after centrifugation.
  • PVC polyvinyl chloride
  • DEHP di-(2-ethylhexyl) phthalate
  • AS3 dextrose
  • Oxygen was removed from the warm RBCs by flushing the blood bags with argon 7-10 times, which reduced the oxygen level of the RBCs to between 8% and 5%, respectively, of their saturation levels.
  • Each unit of blood was sub-divided (about 120 mL aliquots) into pediatric DEHP plasticized PVC transfer bags with 150 mL capacity.
  • transfer bags were stored in an anaerobic chamber filled with an inert gas such as argon. Blood bag gas exchange was further enhanced by 2-3 cycles of exposing the anaerobic chamber to partial vacuum followed by filling with the appropriate gas.
  • a hydrogen generating system with a palladium catalyst was placed in the anaerobic chamber that houses the stored blood to continuously remove emerging traces of O 2 .
  • FIG. 1 the effect of different storage gases as a function of time on the accumulation of membrane vesicles during storage of red blood cells treated with ammonium phosphate at 4°C is shown.
  • the amounts of protein obtained in the form of membrane vesicles that are released by red blood cells during storage with AS3 (open circles), EAS2 (Xs), and EAS2 plus argon (+s) are presented. Data points represent the average of 5 individuals.
  • Figure 2 shows the effect of different storage gases as a function of time on the rate of hemolysis during storage of red blood cells treated with ammonium phosphate at 4°C.
  • Percent hemolysis with AS3 open circles
  • EAS2 Xs
  • EAS2 plus Ar (+s) are presented.
  • Data points represent the average value of 10 (AS3) or 5 (others) individuals.
  • the extent of hemolysis in all samples was somewhat higher than expected for banked blood as a consequence of the inversion and mixing that is required prior to repeated sampling of refrigerated RBCs for the in vitro diagnostics. It is again clearly seen that the percent hemolysis improves when the RBC suspension is deprived of oxygen.
  • Figure 3 shows the effect of different storage gases as a function of time on the ATP concentration during storage of red blood cells at 4°C in the presence and absence of ammonium phosphate.
  • Total cellular ATP is given as ⁇ mol ATP/g Hb.
  • Symbols are: AS3 control (open circles), EAS2 (Xs), and EAS2 plus argon (+s). Data points represent average values for 5-10 individuals. Oxygen-depleted samples sustained even higher levels of ATP than those with the (NH 4 ) 3 P0 4 additive, over the 11 weeks investigated.
  • Figure 4 shows the effect of oxygen removal on total red blood cell ATP, extent of hemolysis, and quantity of shed vesicles for red blood cells stored for 3.5 weeks at 4°C, relative to an untreated control sample.
  • Six units of packed red blood cells were stored in Adsol or AS3 preserving solutions for 3-4 days at a commercial blood bank.
  • Approximately equal volumes of ultra-pure Ar were introduced into the blood bag containing -300 mL of cells at 22°C and horizontally and gently agitated (40 rpm). The gas was exchanged 7 times over a 4 hour period, at which point the oxygen saturation of hemoglobin was measured to be -5%.
  • the cells were then placed in 150 mL transfer bags housed in gas-tight canisters containing 90% Ar,

Abstract

A cost-effective, 4 °C storage procedure that preserves red cell quality and prolongs post-transfusion in vivo survival is described. Preservation of adenosine triphosphate levels and reduction in hemolysis and in membrane vesicle production of red blood cells stored at 4 °C for prolonged periods of time is achieved by removing oxygen therefrom at the time of storage. Adenosine triphosphate levels of the stored red blood cells are boosted in some samples by addition of ammonium phosphate.

Description

METHOD USING OXYGEN REMOVAL FOR EXTENDING THE USEFUL SHELF-LIFE OF REFRIGERATED RED BLOOD CELLS
FIELD OF THE INVENTION The present invention relates generally to the liquid preservation of blood and, more particularly, to the refrigerated storage of blood in the absence of oxygen. The invention was made with government support under Contract No. W-7405-ENG-36 awarded by the U.S. Department of Energy to the Regents of The University of California. The government has certain rights in the invention. BACKGROUND OF THE INVENTION
The current blood supply is considerably smaller than the need therefor. Stored blood is considered unusable after about 5-6 weeks of steady deterioration in storage as determined by the inability of such cells to survive in the circulation after transfusion, which in part is caused by hemoglobin oxidation and degradation and adenosine triphosphate (ATP) depletion. Moreover, the risks involved in receiving blood from nonautologous donors remains significant. In order to address current needs, blood storage techniques must be simple, inexpensive and long-term.
Red blood cells (RBCs) survive for about 4 months under conditions of turbulent flow in the body without protein synthesis. Oxygen (02) is essential for the conversion of hemoglobin (Hb) to met-Hb, the breakdown of which produces toxic products such as hemichrome, hemin and free Fe3+. Together with 02, these products catalyze the formation of hydroxyl radicals (OH«), and both OH* and the met-Hb breakdown products damage the red cell lipid membrane, the membrane skeleton, and the cell contents. As will be discussed hereinbelow, current approaches to red cell preservation do not address the hemoglobin breakdown damage pathway.
Refrigeration reversibly disables the enzymes essential for met-Hb reduction in vivo, increases the solubility of damaging O2 (almost by a factor of 2) in the environment of the red blood cells, and permits the level of ATP to decrease by diminishing the glycolytic rate (at 4°C the rate is about 1% of that found at 37°C). Reduction of red cell ATP concentration results in echinocyte (an unstable form of red blood cells) formation, increased rates of membrane vesiculation, loss of red cell surface area, and accelerated sequestration by splenic macrophages. Vesiculation continues throughout the cold storage period, is exacerbated by echinocyte formation, and decreases red blood cell survival by decreasing red blood cell membrane area.
The effects of elevation and preservation of ATP levels in blood storage situations has been studied. For example, in "Studies In Red Blood Cell Preservation-7. In Vivo and in Vitro Studies With A Modified Phosphate-Ammonium Additive Solution," by Greenwalt et al., Vox Sang 65, 87-94 (1993), the authors determined that the experimental additive solution (EAS-2) containing in mM: 20 NH4CI, 30 Na2HP04, 2 adenine, 110 dextrose, 55 mannitol, pH 7.15, is useful in extending the storage shelf-life of human RBCs from the current standard of 5-6 weeks to an improved standard of 8-9 weeks. Packed RBCs are suitable for transfusion following the removal of the supernatant with a single washing step. Greenwalt et al. also conclude that factors other than ATP concentration appear to play an increasingly important role in determining RBC viability after 50 days of storage. They cite the results of L. Wood and E. Beutler in "The Viability Of Human Blood Stored In Phosphate Adenine Media," Transfusion 7, 401-408 (1967), find in their own experiments that the relationship between ATP concentration and 24-hour RBC survival measurements appears to become less clear after about 8 weeks of storage. E. Beutler and C. West restate that the relationship between red cell ATP concentration and viability is a weak one after prolonged periods of storage in "Storage Of Red Cell Concentrates In CPD-A2 For 42 and 49 Days," J. Lab. Clin. Med. 102, 53-62 (1983).
In "Effects Of Oxygen On Red Cells During Liquid Storage at +4°C," by Hogman et al., Vox Sang 51 , 27-34 (1986), the authors discuss that red cell content of ATP is slightly better maintained at anaerobic than at aerobic storage after 2-3 weeks. Venous blood was refrigerated and deprived of additional oxygen during storage, by placing the oxygen-permeable storage bags in a nitrogen environment and thereby gradually reducing the level of oxygen saturation. The reduction in oxygen concentration occurs slowly during storage at 4°C, and is far from complete, starting at -60% and reaching -30% hemoglobin saturation at 5 weeks. No conclusion could be drawn concerning the effects of this procedure on the overall quality of stored cells. These authors did not address or significantly reduce the oxygen- dependent damage to hemoglobin and the oxygen-mediated damage caused by hemoglobin breakdown products.
Accordingly, it is an object of the present invention to provide a procedure for blood storage which addresses the problems of hemoglobin degradation, red blood cell lysis (hemolysis) and ATP depletion in a manner consistent with the practice of autologous transfusion and enhanced heterologous transfusion logistics, and which achieves significant prolongation of the time during which refrigerated storage of red blood cells is not detrimental to their subsequent use.
Another object of the present invention is to provide a procedure for prolonged blood storage while minimizing the complexity of the procedures required for preparing transfusible samples.
Additional objects, advantages and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following or may be learned by practice of the invention. The objects and advantages of the invention may be realized and attained by means of the instrumentalities and combinations particularly pointed out in the appended claims.
SUMMARY OF THE INVENTION To achieve the foregoing and other objects, and in accordance with the purposes of the present invention, as embodied and broadly described herein, the method for storing red blood cells hereof includes the steps of: mixing a sample of whole blood containing the red blood cells to be stored with an anticoagulant solution, forming thereby a first suspension of red blood cells, concentrating the red blood cells from the liquid portion (plasma) of the first suspension, forming thereby a mass of packed red blood cells, mixing the packed red blood cells so produced with an additive solution which includes glucose, adenine, and salts, forming thereby a second suspension of red blood cells, removing the oxygen from the second suspension of red blood cells, and cooling the second suspension of red blood cells to 4°C. Preferably, no further exposure of the cooled red blood cells to oxygen is permitted. In another aspect of the present invention, and in accordance with its objects and purposes, the method for storing red blood cells hereof includes the steps of: forming a mass of packed red blood cells, mixing the packed red blood cells with an additive solution which includes glucose, adenine, and salts, forming thereby a suspension of red blood cells removing the oxygen from the suspension of red blood cells, and cooling the suspension of red blood cells to 4°C.
Preferably, no further exposure of the cooled red blood cells to oxygen is permitted.
Benefits and advantages of the present invention include the preservation of ATP levels and the reduction of hemolysis and accumulation of membrane vesicles in the refrigerated RBCs, as a consequence of creating an environment (02 removal) that prevents hemoglobin degradation, with the result that useful refrigerated storage periods may be prolonged.
BRIEF DESCRIPTION OF THE DRAWINGS The accompanying drawings, which are incorporated in and form a part of the specification, illustrate an embodiment of the present invention and, together with the description, serve to explain the principles of the invention. In the drawings:
FIGURE 1 shows the effect of different storage gases as a function of time on the quantity of membrane vesicles accumulated during storage of red blood cells treated with ammonium phosphate at 4°C.
FIGURE 2 shows the effect of different storage gases as a function of time on the rates of hemolysis during storage of red blood cells treated with ammonium phosphate at 4°C.
FIGURE 3 shows the effect of different storage gases as a function of time on the cellular ATP levels during storage of red blood cells at 4°C in the presence and absence of ammonium phosphate.
FIGURE 4 shows the effect of oxygen removal on total red blood cell ATP, extent of hemolysis, and quantity of shed vesicles for red blood cells stored for 3.5 weeks at 4°C, relative to an untreated control sample. DETAILED DESCRIPTION
Briefly, the present invention includes improvement of the in vivo survival characteristics of transfused red blood cells that have been stored at 4°C for prolonged periods of time by removing oxygen therefrom at the time of storage, and preventing any further exposure of the stored RBCs to oxygen. The in vitro diagnostics of hemolysis, vesicle production and ATP levels, when taken together, provide a useful indication of in vivo survival. Moreover, adenosine triphosphate levels within the stored red blood cells have been boosted in some samples by addition of ammonium phosphate. Oxygen removal, and the effects of various additive solutions were investigated with red blood cells stored in standard polyvinyl chloride (PVC) blood bags with di-(2-ethylhexyl) phthalate (DEHP) plasticizer containing citrate, phosphate, sodium chloride, adenine, and dextrose (anticoagulant/buffer solution, AS3) after centrifugation. Oxygen was removed from the warm RBCs by flushing the blood bags with argon 7-10 times, which reduced the oxygen level of the RBCs to between 8% and 5%, respectively, of their saturation levels. Each unit of blood was sub-divided (about 120 mL aliquots) into pediatric DEHP plasticized PVC transfer bags with 150 mL capacity. Blood was stored at 4°C in a light-shielded blood bank refrigerator and samples were withdrawn via a sterile septum sampling port. Rapid cooling after rapid purging is essential to prevent lactic acid buildup in the RBCs. Moreover, it should be mentioned that the oxygen can also be removed after the RBCs are cooled. However, since the RBCs are unprotected from the effects of oxidation once cooled, and since oxygen removal is more rapid at 37°C or 21 °C when compared with 4°C, the preferred procedure is to cool them after oxygen removal. As reported by Hόgman et al., supra, conventional PVC blood storage bags are permeable to 02. It takes about 4 weeks of conventional storage for a unit of packed red blood ceils to become fully oxygenated. In order to evaluate the long- term effects of replacing the storage gas, transfer bags were stored in an anaerobic chamber filled with an inert gas such as argon. Blood bag gas exchange was further enhanced by 2-3 cycles of exposing the anaerobic chamber to partial vacuum followed by filling with the appropriate gas. In addition, a hydrogen generating system with a palladium catalyst was placed in the anaerobic chamber that houses the stored blood to continuously remove emerging traces of O2.
The effect of ammonium phosphate additive solution for boosting ATP called
EAS2 and described by Greenwalt et al., supra, was further investigated by the present inventors. As stated above, this additive produces a gradual elevation of
ATP which is sustained by the red blood cells during extended periods of storage at
4°C.
Reference will now be made in detail to the present preferred embodiments of the present invention, examples of which are illustrated in the accompanying drawings. Turning now to Figure 1 , the effect of different storage gases as a function of time on the accumulation of membrane vesicles during storage of red blood cells treated with ammonium phosphate at 4°C is shown. The amounts of protein obtained in the form of membrane vesicles that are released by red blood cells during storage with AS3 (open circles), EAS2 (Xs), and EAS2 plus argon (+s) are presented. Data points represent the average of 5 individuals. The addition of 10 mM NH4 + as NH4CI and 20 mM P04 3 as Na2HP04 (EAS2), appreciably elevated ATP levels and decreased vesicle production throughout the storage period. It is seen that removal of O2 with argon and an O2 scavenger (H2/Pd) further decreases the vesicle production. Oxygen removal with argon in the presence of (NH4)3P04 also reduced rates of hemolysis and further boosted ATP levels above the levels achieved with the addition of (NH4)3P04 in the absence of 02 removal.
Figure 2 shows the effect of different storage gases as a function of time on the rate of hemolysis during storage of red blood cells treated with ammonium phosphate at 4°C. Percent hemolysis with AS3 (open circles), EAS2 (Xs), and EAS2 plus Ar (+s) are presented. Data points represent the average value of 10 (AS3) or 5 (others) individuals. The extent of hemolysis in all samples was somewhat higher than expected for banked blood as a consequence of the inversion and mixing that is required prior to repeated sampling of refrigerated RBCs for the in vitro diagnostics. It is again clearly seen that the percent hemolysis improves when the RBC suspension is deprived of oxygen.
Figure 3 shows the effect of different storage gases as a function of time on the ATP concentration during storage of red blood cells at 4°C in the presence and absence of ammonium phosphate. Total cellular ATP is given as μmol ATP/g Hb. Symbols are: AS3 control (open circles), EAS2 (Xs), and EAS2 plus argon (+s). Data points represent average values for 5-10 individuals. Oxygen-depleted samples sustained even higher levels of ATP than those with the (NH4)3P04 additive, over the 11 weeks investigated.
Having generally described the invention, the following example sets forth the details of the method hereof.
EXAMPLE
Figure 4 shows the effect of oxygen removal on total red blood cell ATP, extent of hemolysis, and quantity of shed vesicles for red blood cells stored for 3.5 weeks at 4°C, relative to an untreated control sample. Six units of packed red blood cells were stored in Adsol or AS3 preserving solutions for 3-4 days at a commercial blood bank. Approximately equal volumes of ultra-pure Ar were introduced into the blood bag containing -300 mL of cells at 22°C and horizontally and gently agitated (40 rpm). The gas was exchanged 7 times over a 4 hour period, at which point the oxygen saturation of hemoglobin was measured to be -5%. The cells were then placed in 150 mL transfer bags housed in gas-tight canisters containing 90% Ar,
10% H2, and a palladium catalyst. The blood was maintained at 4°C. It is readily observed that all of the indicia of in vivo survival are improved by the removal of oxygen only. The results are understated, since the blood samples employed had already been chilled in the presence of oxygen for 2-4 days.
The foregoing description of the invention has been presented for purposes of illustration and description and is not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teaching.
The embodiments were chosen and described in order to best explain the principles of the invention and its practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended hereto.

Claims

WHAT IS CLAIMED IS:
1. A method for storing red blood cells which comprises the steps of: a. mixing a sample of whole blood containing the red blood cells to be stored with an anticoagulant solution, forming thereby a first suspension of red blood cells; b. concentrating the red blood cells from the liquid portion of the first suspension, forming thereby a mass of packed red blood cells; c. mixing the packed red blood cells so produced with an additive solution which includes glucose, adenine, and salts, forming thereby a second suspension of red blood cells; d. removing the oxygen from the second suspension of red blood cells; and e. cooling the second suspension of red blood cells to 4°C.
2. The method for storing red blood cells as described in Claim 1 , wherein said step of removing the oxygen from the second suspension of red blood cells comprises repeatedly flushing the second suspension of red blood cells with an inert gas.
3. The method for storing red blood cells as described in Claim 1 , further comprising the step of storing the second suspension of red blood cells in an oxygen- permeable enclosure which is located in an oxygen-free environment.
4. The method for storing red blood cells as described in Claim 1 , further comprising the step of storing the second suspension of red blood cells in an oxygen- permeable enclosure which is located in an oxygen-free environment containing oxygen scavenging materials.
5. The method for storing red blood cells as described in Claim 1 , further comprising the step of adding ammonium phosphate to the second suspension to boost adenosine triphosphate levels in the red blood cells.
6. The method for storing red blood cells as described in Claim 1 , wherein said step of removing oxygen from the second suspension takes place before said step of cooling the second suspension to 4°C.
7. The method for storing red blood cells as described in Claim 1 , further comprising the step of washing the red blood cells with a saline solution containing glucose before their use in order to lower the concentration of ammonium phosphate therein.
8. A method for storing red blood cells which comprises the steps of: a. forming a mass of packed red blood cells; b. mixing the packed red blood cells with an additive solution which includes glucose, adenine, and salts, forming thereby a suspension of red blood cells; c. removing the oxygen from the suspension of red blood cells; and d. cooling the suspension of red blood cells to 4°C.
9. The method for storing red blood cells as described in Claim 8, wherein said step of removing the oxygen from the suspension of red blood cells comprises repeatedly flushing the suspension of red blood cells with an inert gas.
10. The method for storing red blood cells as described in Claim 8, further comprising the step of storing the suspension of red blood cells in an oxygen- permeable enclosure which is located in an oxygen-free environment.
11. The method for storing red blood cells as described in Claim 8, further comprising the step of storing the suspension of red blood cells in an oxygen- permeable enclosure which is located in an oxygen-free environment containing oxygen scavenging materials.
12. The method for storing red blood cells as described in Claim 8, further comprising the step of adding ammonium phosphate to the suspension to boost adenosine triphosphate levels in the red blood cells.
13. The method for storing red blood cells as described in Claim 8, wherein said step of removing oxygen from the suspension takes place before said step of cooling the suspension to 4°C.
14. The method for storing red blood cells as described in Claim 8, further comprising the step of washing the red blood cells with a saline solution containing glucose before their use in order to lower the concentration of ammonium phosphate therein.
PCT/US1996/009005 1995-06-05 1996-06-05 Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells WO1996039026A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
BR9608404-9A BR9608404A (en) 1995-06-05 1996-06-05 Process for storing red blood cells.
CA002223130A CA2223130C (en) 1995-06-05 1996-06-05 Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells
DE69626204T DE69626204T2 (en) 1995-06-05 1996-06-05 THE REMOVAL OF OXYGEN-CONTAINING METHOD FOR EXTENDING THE USEFUL STORAGE PERIOD OF CHILLED RED BLOOD CELLS
AU60470/96A AU710467B2 (en) 1995-06-05 1996-06-05 Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells
AT96918133T ATE232359T1 (en) 1995-06-05 1996-06-05 METHOD INCLUDING OXYGEN ELIMINATION FOR EXTENSING THE USABLE STORAGE TIME OF COOLED RED BLOOD CELLS
EP96918133A EP0830058B1 (en) 1995-06-05 1996-06-05 Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells
JP50143097A JP4303786B2 (en) 1995-06-05 1996-06-05 Extending the effective shelf life of frozen red blood cells by oxygen removal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/473,675 US5624794A (en) 1995-06-05 1995-06-05 Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas
US08/473,675 1996-06-05

Publications (1)

Publication Number Publication Date
WO1996039026A1 true WO1996039026A1 (en) 1996-12-12

Family

ID=23880537

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/009005 WO1996039026A1 (en) 1995-06-05 1996-06-05 Method using oxygen removal for extending the useful shelf-life of refrigerated red blood cells

Country Status (13)

Country Link
US (1) US5624794A (en)
EP (1) EP0830058B1 (en)
JP (1) JP4303786B2 (en)
KR (1) KR100395033B1 (en)
CN (1) CN1153512C (en)
AT (1) ATE232359T1 (en)
AU (1) AU710467B2 (en)
BR (1) BR9608404A (en)
CA (1) CA2223130C (en)
DE (1) DE69626204T2 (en)
ES (1) ES2194993T3 (en)
RU (1) RU2181542C2 (en)
WO (1) WO1996039026A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8512942B2 (en) 2010-11-29 2013-08-20 New York Blood Center, Inc. Method of blood pooling and storage
EP2691160A1 (en) * 2011-03-28 2014-02-05 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US9315775B2 (en) 2011-03-16 2016-04-19 Mayo Foundation For Medical Education And Research Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
US9801784B2 (en) 2015-04-23 2017-10-31 New Health Sciences, Inc. Anaerobic blood storage containers
US9844615B2 (en) 2009-10-12 2017-12-19 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US9877476B2 (en) 2013-02-28 2018-01-30 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
US9977037B2 (en) 2012-05-22 2018-05-22 New Health Sciences, Inc. Capillary network devices and methods of use
US10058091B2 (en) 2015-03-10 2018-08-28 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US10065134B2 (en) 2010-05-05 2018-09-04 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
US10136635B2 (en) 2010-05-05 2018-11-27 New Health Sciences, Inc. Irradiation of red blood cells and anaerobic storage
US10251387B2 (en) 2010-08-25 2019-04-09 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
US10583192B2 (en) 2016-05-27 2020-03-10 New Health Sciences, Inc. Anaerobic blood storage and pathogen inactivation method
US11013771B2 (en) 2015-05-18 2021-05-25 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162396A (en) * 1997-04-26 2000-12-19 The Regents Of The University Of California Blood storage device and method for oxygen removal
US5789151A (en) * 1997-05-15 1998-08-04 The Regents Of The University Of California Prolonged cold storage of red blood cells by oxygen removal and additive usage
US7498156B2 (en) * 1998-07-21 2009-03-03 Caridianbct Biotechnologies, Llc Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7049110B2 (en) * 1998-07-21 2006-05-23 Gambro, Inc. Inactivation of West Nile virus and malaria using photosensitizers
US20030215784A1 (en) * 1998-07-21 2003-11-20 Dumont Larry Joe Method and apparatus for inactivation of biological contaminants using photosensitizers
US20070099170A1 (en) * 1998-07-21 2007-05-03 Navigant Biotechnologies, Inc. Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate
US7985588B2 (en) * 2000-06-02 2011-07-26 Caridianbct Biotechnologies, Llc Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
TW590780B (en) * 2000-06-02 2004-06-11 Gambro Inc Additive solutions containing riboflavin
US7648699B2 (en) * 2000-06-02 2010-01-19 Caridianbct Biotechnologies, Llc Preventing transfusion related complications in a recipient of a blood transfusion
US6548241B1 (en) * 2000-11-28 2003-04-15 Gambro, Inc. Storage solution containing photosensitizer for inactivation of biological contaminants
CA2467223A1 (en) * 2001-11-16 2003-05-30 Hollinger Digital, Inc. Method for extending the useful shelf-life of refrigerated red blood cells by nutrient supplementation
AU2002348283A1 (en) * 2001-11-16 2003-06-10 Hemanext, Llc Additive solution for blood preservation
US20080299538A1 (en) * 2003-02-28 2008-12-04 Caridianbct Biotechnologies, Llc Pathogen Inactivation of Whole Blood
US8828226B2 (en) 2003-03-01 2014-09-09 The Trustees Of Boston University System for assessing the efficacy of stored red blood cells using microvascular networks
US9314014B2 (en) 2004-02-18 2016-04-19 University Of Maryland, Baltimore Compositions and methods for the storage of red blood cells
CN1325518C (en) * 2005-09-09 2007-07-11 李勇 Cell membrane antigen preservation method and magnetic particle envelope human cell membrane antigen
WO2008039382A2 (en) * 2006-09-21 2008-04-03 Kyphon Sarl Diammonium phosphate and other ammonium salts and their use in preventing clotting
WO2009026073A1 (en) * 2007-08-22 2009-02-26 Caridianbct Biotechnologies, Llc Prevention of transfusion related acute lung injury using riboflavin and light
US8871434B2 (en) * 2008-03-21 2014-10-28 Fenwal, Inc. Red blood cell storage medium for extended storage
US8968992B2 (en) * 2008-03-21 2015-03-03 Fenwal, Inc. Red blood cell storage medium for extended storage
EP2389064A4 (en) 2009-10-12 2014-10-01 New Health Sciences Inc Oxygen depletion devices and methods for removing oxygen from red blood cells
JP6199557B2 (en) * 2009-10-12 2017-09-20 ニュー ヘルス サイエンシーズ、インク．Ｎｅｗ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． Blood storage bag system and depletion device with oxygen and carbon dioxide depletion capability
WO2011049709A1 (en) 2009-10-23 2011-04-28 Fenwal, Inc. Methods and systems for providing red blood cell products with reduced plasma
WO2013006631A1 (en) 2011-07-05 2013-01-10 New Health Sciences, Inc. A system for extended storage of red blood cells and methods of use
AR088166A1 (en) 2011-09-26 2014-05-14 Rich Products Corp METHOD FOR THE PRESERVATION OF LIVE FABRIC
CN110583627A (en) * 2012-11-30 2019-12-20 里奇技术股份有限公司 Method for preserving red blood cells
JP5935954B2 (en) * 2014-03-13 2016-06-15 ＭｉＺ株式会社 Method for producing hydrogen-containing biological fluid and exterior body therefor
BR112018076512A2 (en) 2016-06-23 2019-04-02 New Health Sciences, Inc. method for managing adverse events in patient populations requiring transfusion
MX2019013785A (en) 2017-05-19 2020-01-13 New Health Sciences Inc Methods and treatment of trauma.
CN107873696B (en) * 2017-11-14 2020-12-11 上海市血液中心 Preserving fluid for red blood cells of animals in family of bear and application thereof
CN113365642A (en) 2018-11-16 2021-09-07 希玛奈克斯特股份有限公司 Methods for controlling adverse events in inflammatory patients
CN110447634A (en) * 2019-06-27 2019-11-15 浙江省疾病预防控制中心 A kind of monkey red blood cells save liquid and application
CN110199987A (en) * 2019-07-22 2019-09-06 深圳市未来细胞生命科技有限公司 A kind of mesenchyme stem cell preserving fluid and its store method and application
CN114288484B (en) * 2021-12-10 2023-01-03 中国人民解放军军事科学院军事医学研究院 Low oxygen filtration blood bag system, blood bag system and blood processing method
WO2024064723A1 (en) 2022-09-20 2024-03-28 Hemanext Inc. Oxygen reduced blood for use in the treatment of traumatic brain injury accompanied by hemorrhagic shock

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902701A (en) * 1982-04-27 1990-02-20 Burroughs Welcome Co. Tetrazolyl substituted tricyclic compounds and pharmacological compositions thereof
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902701A (en) * 1982-04-27 1990-02-20 Burroughs Welcome Co. Tetrazolyl substituted tricyclic compounds and pharmacological compositions thereof
US5476764A (en) * 1994-09-16 1995-12-19 The Regents Of The University Of California Method using CO for extending the useful shelf-life of refrigerated red blood cells

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOMED. BIOCHIM. ACTA, 1983, Vol. 42, HOGMAN et al., "Cell Shape and Total Adenylate Concentration as Important Factors for Posttransfusion Survival of Erythrocytes", pages S327-S331. *
BIOMED. BIOCHIM. ACTA, 1987, Vol. 46, HOGMAN et al., "Effects of Oxygen and Mixing on Red Cells Stored in Plastic Bags at +4°C", pages S290-S294. *
VOX SANG, 1986, Vol. 51, HOGMAN et al., "Effects of Oxygen on Red Cells During Liquid Storage at +4°C", pages 27-34. *
VOX SANG, 1993, Vol. 65, GREENWALT et al., "Studies in Red Blood Cell Preservation 7. In Vivo and in Vitro Studies with a Modified Phosphate-Ammonium Additive Solution", pages 87-94. *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11433164B2 (en) 2009-10-12 2022-09-06 Hemanext Inc. System for extended storage of red blood cells and methods of use
US10603417B2 (en) 2009-10-12 2020-03-31 Hemanext Inc. System for extended storage of red blood cells and methods of use
US9844615B2 (en) 2009-10-12 2017-12-19 New Health Sciences, Inc. System for extended storage of red blood cells and methods of use
US10136635B2 (en) 2010-05-05 2018-11-27 New Health Sciences, Inc. Irradiation of red blood cells and anaerobic storage
US10065134B2 (en) 2010-05-05 2018-09-04 New Health Sciences, Inc. Integrated leukocyte, oxygen and/or CO2 depletion, and plasma separation filter device
US11284616B2 (en) 2010-05-05 2022-03-29 Hemanext Inc. Irradiation of red blood cells and anaerobic storage
US10251387B2 (en) 2010-08-25 2019-04-09 New Health Sciences, Inc. Method for enhancing red blood cell quality and survival during storage
US9982230B2 (en) 2010-11-29 2018-05-29 New York Blood Center, Inc. Uniform dose pooled blood products
US9394518B2 (en) 2010-11-29 2016-07-19 The New York Blood Center, Inc. Method of preparing red blood cell and platelet products
US8512942B2 (en) 2010-11-29 2013-08-20 New York Blood Center, Inc. Method of blood pooling and storage
US8968993B2 (en) 2010-11-29 2015-03-03 The New York Blood Center, Inc. Method of blood pooling and storage
US10385317B2 (en) 2010-11-29 2019-08-20 New York Blood Center, Inc. Method of blood pooling storage
US10612000B2 (en) 2010-11-29 2020-04-07 New York Blood Center, Inc. Method of blood pooling and storage
US9315775B2 (en) 2011-03-16 2016-04-19 Mayo Foundation For Medical Education And Research Methods and materials for prolonging useful storage of red blood cell preparations and platelet preparations
US9968718B2 (en) 2011-03-28 2018-05-15 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US9067004B2 (en) 2011-03-28 2015-06-30 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
EP2691160A4 (en) * 2011-03-28 2015-04-08 New Health Sciences Inc Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
EP2691160A1 (en) * 2011-03-28 2014-02-05 New Health Sciences, Inc. Method and system for removing oxygen and carbon dioxide during red cell blood processing using an inert carrier gas and manifold assembly
US9977037B2 (en) 2012-05-22 2018-05-22 New Health Sciences, Inc. Capillary network devices and methods of use
US10687526B2 (en) 2013-02-28 2020-06-23 Hemanext Inc. Gas depletion and gas addition devices for blood treatment
US9877476B2 (en) 2013-02-28 2018-01-30 New Health Sciences, Inc. Gas depletion and gas addition devices for blood treatment
US10058091B2 (en) 2015-03-10 2018-08-28 New Health Sciences, Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US11350626B2 (en) 2015-03-10 2022-06-07 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof (ORDKit)
US11375709B2 (en) 2015-03-10 2022-07-05 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US11638421B2 (en) 2015-03-10 2023-05-02 Hemanext Inc. Oxygen reduction disposable kits, devices and methods of use thereof
US10849824B2 (en) 2015-04-23 2020-12-01 Hemanext Inc. Anaerobic blood storage containers
US9801784B2 (en) 2015-04-23 2017-10-31 New Health Sciences, Inc. Anaerobic blood storage containers
US11013771B2 (en) 2015-05-18 2021-05-25 Hemanext Inc. Methods for the storage of whole blood, and compositions thereof
US10583192B2 (en) 2016-05-27 2020-03-10 New Health Sciences, Inc. Anaerobic blood storage and pathogen inactivation method
US11147876B2 (en) 2016-05-27 2021-10-19 Hemanext Inc. Anaerobic blood storage and pathogen inactivation method
US11911471B2 (en) 2016-05-27 2024-02-27 Hemanext Inc. Anaerobic blood storage and pathogen inactivation method

Also Published As

Publication number Publication date
ATE232359T1 (en) 2003-02-15
EP0830058A4 (en) 1999-04-14
AU6047096A (en) 1996-12-24
ES2194993T3 (en) 2003-12-01
JPH11506777A (en) 1999-06-15
DE69626204D1 (en) 2003-03-20
KR19990022393A (en) 1999-03-25
EP0830058B1 (en) 2003-02-12
US5624794A (en) 1997-04-29
RU2181542C2 (en) 2002-04-27
CA2223130A1 (en) 1996-12-12
KR100395033B1 (en) 2003-12-31
BR9608404A (en) 1999-11-30
CN1153512C (en) 2004-06-16
AU710467B2 (en) 1999-09-23
CN1195965A (en) 1998-10-14
EP0830058A1 (en) 1998-03-25
JP4303786B2 (en) 2009-07-29
CA2223130C (en) 2005-02-08
DE69626204T2 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
US5624794A (en) Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas
US5789151A (en) Prolonged cold storage of red blood cells by oxygen removal and additive usage
US4812310A (en) Preserving solution for blood or packed blood cells and method for preserving blood or packed blood cells by using the same
JP4564260B2 (en) Additive solution for blood storage
US20180064858A1 (en) System for Extended Storage of Red Blood Cells and Methods of Use
CA2840901C (en) A system for extended storage of red blood cells and methods of use
US4473552A (en) Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells
EP0313808A2 (en) Synthetic, plasma-free, transfusible storage medium for red blood cells
JP2005535279A (en) A method for extending the effective shelf life of refrigerated red blood cells by nutritional supplementation
EP0237863A1 (en) Synthetic, plasma-free, transfusible platelet storage medium.
WO1990015612A1 (en) Glucose free primary anticoagulant for blood
EP2925123B1 (en) Erythrocyte preservation method
JPH041135A (en) Preservation liquid for platelet
MXPA97009537A (en) Method using elimination of oxygen to extend the useful life in anaquel de celulas sanguineas rojas refrigera
IE53734B1 (en) Anaerobic method for preserving whole blood, tissue and components containing living mammalian cells
NZ201599A (en) Preserving biological substances containing mammalian cells

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96196053.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1997 501430

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2223130

Country of ref document: CA

Ref document number: 2223130

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1997/009537

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1996918133

Country of ref document: EP

Ref document number: 1019970708873

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1996918133

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019970708873

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1996918133

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1019970708873

Country of ref document: KR